Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.05, Zacks reports. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%.
Mersana Therapeutics Stock Performance
MRSN opened at $0.52 on Monday. The firm has a market cap of $64.66 million, a P/E ratio of -0.86 and a beta of 1.39. Mersana Therapeutics has a 1-year low of $0.48 and a 1-year high of $6.28. The company has a 50 day simple moving average of $0.84 and a two-hundred day simple moving average of $1.57. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35.
Wall Street Analysts Forecast Growth
A number of analysts have recently commented on the stock. Wedbush reiterated an "outperform" rating and issued a $4.00 price target (down from $7.00) on shares of Mersana Therapeutics in a research note on Friday, January 10th. William Blair assumed coverage on shares of Mersana Therapeutics in a research report on Thursday, February 6th. They set an "outperform" rating for the company. Finally, Citigroup assumed coverage on shares of Mersana Therapeutics in a research report on Friday, November 15th. They set a "buy" rating and a $5.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $4.25.
Check Out Our Latest Stock Analysis on MRSN
Mersana Therapeutics Company Profile
(
Get Free Report)
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Mersana Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mersana Therapeutics wasn't on the list.
While Mersana Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
